Literature DB >> 15929865

Statins and CVD prevention in the diabetic population: implications of the CARDS trial.

Omar Murad, John Palmer, James Sowers, Samy I McFarlane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15929865     DOI： 10.1007/s11892-005-0008-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN： 1534-4827            Impact factor:   4.810


× No keyword cloud information.
  15 in total

Review 1.  Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond.

Authors:  S I McFarlane; R Muniyappa; R Francisco; J R Sowers
Journal:  J Clin Endocrinol Metab       Date:  2002-04       Impact factor: 5.958

2.  Statins for all patients with type 2 diabetes: not so soon.

Authors:  Abhimanyu Garg
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

3.  Intensive statin therapy--a sea change in cardiovascular prevention.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

4.  Statins for patients with type 2 diabetes.

Authors:  Giuseppe Pimpinella; Renato Bertini Malgarini; Nello Martini
Journal:  Lancet       Date:  2004 Nov 27-Dec 3       Impact factor: 79.321

5.  Statins for atherosclerosis--as good as it gets?

Authors:  Michael R Ehrenstein; Elizabeth C Jury; Claudia Mauri
Journal:  N Engl J Med       Date:  2005-01-06       Impact factor: 91.245

6.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

7.  Effects of lovastatin on cognitive function and psychological well-being.

Authors:  M F Muldoon; S D Barger; C M Ryan; J D Flory; J P Lehoczky; K A Matthews; S B Manuck
Journal:  Am J Med       Date:  2000-05       Impact factor: 4.965

8.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

9.  Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.

Authors:  Michael Brandle; Mayer B Davidson; David L Schriger; Brett Lorber; William H Herman
Journal:  Diabetes Care       Date:  2003-06       Impact factor: 19.112

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245
View more
  1 in total

Review 1.  Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts: A Meta-Analysis.

Authors:  Haroon Kamran; Eric Kupferstein; Navneet Sharma; Jocelyne G Karam; Alyson K Myers; Irini Youssef; James R Sowers; Deborah R Gustafson; Moro O Salifu; Samy I McFarlane
Journal:  Cardiorenal Med       Date:  2018-01-22       Impact factor: 2.041
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.